Published on
by
Mail & Guardian

Under the Current Rules, Vaccines Are Only Going To Rich Countries That Can Afford It

Despite Bill Gates’ stated commitment to an equitable distribution of the Covid vaccine, he is refusing to back South Africa and India’s calls for a waiver on patents.

In this screengrab, (L-R) Melinda Gates and Bill Gates speak during "One World: Together At Home" presented by Global Citizen on April, 18, 2020. The global broadcast and digital special was held to support frontline healthcare workers and the COVID-19 Solidarity Response Fund for the World Health Organization, powered by the UN Foundation. (Photo by Getty Images/Getty Images for Global Citizen )

In this screengrab, (L-R) Melinda Gates and Bill Gates speak during "One World: Together At Home" presented by Global Citizen on April, 18, 2020. The global broadcast and digital special was held to support frontline healthcare workers and the COVID-19 Solidarity Response Fund for the World Health Organization, powered by the UN Foundation. (Photo by Getty Images/Getty Images for Global Citizen )

In October 2020, diplomats from South Africa and India approached the World Trade Organisation (WTO) with a revolutionary proposal.

Together, the two countries argued that countries should be allowed to ignore any patents related to Covid-19 vaccines, for the duration of the pandemic. In other words: everyone should be allowed to manufacture the vaccine, without penalty.

In their official communication, the countries said: “As new diagnostics, therapeutics and vaccines for Covid-19 are developed, there are significant concerns [about] how these will be made available promptly, in sufficient quantities and at affordable prices to meet global demand.”

Just a few weeks later, Pfizer and BioNTech announced the first successful phase three trials for a Covid-19 vaccine, followed swiftly by Moderna and AstraZeneca.

In developing countries, jubilation at the prospect of a swift end to the devastating pandemic turned quickly into fear and anger, as it became clear that vaccines would only be made available to the rich, with little thought to equitable distribution. Canada, the worst offender, has pre-ordered so many vaccines that it will be able to vaccinate each of its citizens six times over. In the UK and US, it is four vaccines per person; and two each in the EU and Australia.

The vaccines that have been made available to the developing world are either untested — such as the Chinese and Russian vaccines, for which insufficient clinical trial data has been released — or expensive. South Africa has ordered 1.5-million doses of the AstraZeneca vaccine, but will pay more than double what the EU is paying per dose.

The EU says that it is entitled to a lower price because it invested in the vaccine’s development — nevermind that the AstraZeneca vaccine was literally tested on the bodies of South Africans who volunteered to be part of the clinical trial in Johannesburg.

In lower income countries, the situation is even worse. As of 18 January, 39-million vaccine doses had been administered in the world’s 50 richest countries, compared to just 25 individual doses in low-income countries.

It appears that South Africa and India were right. Under the current rules, the vaccine cannot be made quickly or cheaply enough to meet global demand, which vaccines are only going to those countries that can afford it. This is a “catastrophic moral failure”, said the head of the World Health Organisation (WHO), Tedros Adhanom Ghebreyesus. Some activists have described the situation as a "vaccine apartheid."

"Nor has South Africa and India’s proposal received support from the most influential non-state actor in global public health: Bill Gates."

Nonetheless, the proposal for a patent waiver has been repeatedly rejected at the WTO by wealthier countries including the European Union, the United Kingdom, US and Switzerland; countries which, as Reuters wryly noted, are “all home to major pharmaceutical companies.” They also all enjoy early access to the vaccine.

Nor has South Africa and India’s proposal received support from the most influential non-state actor in global public health: Bill Gates.

SCROLL TO CONTINUE WITH CONTENT

Never Miss a Beat.

Get our best delivered to your inbox.

The pandemic has been good to Gates. In 2020, the Microsoft cofounder added $18-billion to his fortune, which now stands at a cool $131-billion (the annual GDP of Ethiopia, a country of 112-million people, is $96-billion). He is the fourth-richest person in the world.

The Bill and Melinda Gates Foundation has since its inception in 2000 spent more than $54-billion combating diseases such as polio and malaria and bolstering the health systems of developing countries. It funds everything from governments to civil society organisations to health journalism outlets, which means it has an enormous say in how health policy is shaped and communicated. It also contributes 12% of the WHO’s total budget.

But despite Gates’ stated commitment to an equitable distribution of the Covid vaccine, he is refusing to back South Africa and India’s calls for a waiver on patents.

This should not come as a surprise: the Gates Foundation has historically been opposed to efforts to reform intellectual property protections for pharmaceutical companies — putting it at odds with other public health NGOs such as Doctors Without Borders (MSF) — and has in fact lobbied for developing countries to impose even stronger protections for drug companies’ patents. This is perhaps because Gates’ own fortune is built on intellectual property, specifically the copy­rights and patents associated with Windows and Microsoft.

In response to a question from the Mail & Guardian, Gates argued that lifting patents would not make any real difference. “At this point, changing the rules wouldn’t make any additional vaccines available.” That’s because, he claims, there are only a handful of manufacturers in the world with the necessary capacity to make the vaccines, and these are all at capacity already.

This claim is only partially true, as MSF vaccine pharmacist Alain Alsalhani told the M&G. Highly specialised manufacturers are needed to make traditional vaccines, such as the AstraZeneca jab, because this involves isolating and replicating parts of the virus itself.

Only 43 companies are on the WHO’s approved list of vaccine manufacturers, and it could take years to set up new factories that meet the regulations.

But the Pfizer and Moderna vaccines are based on manipulating messenger RNA (mRNA), which appears to be significantly easier to manufacture. Moderna’s vaccines are being produced by Lonza, a Swiss chemicals company with no previous experience of vaccine manufacture. This suggests that the pool of companies that could make the vaccine is much higher, with potentially 10 000 capable companies in India alone.

“If this assumption is verified, and we hope we will have more detailed analysis [soon], then we are changing the story here,” said Alsalhani.

Even then, Alsalhani warns that waiving patent protections is no miracle fix, because the technical challenges are still considerable — especially if the big pharmaceutical companies are unwilling to share their processes. Moderna, for example, has said it will not enforce its patent rights; but Lonza, which actually makes the vaccine, “won’t talk to us” about how it’s actually done, he said.

South Africa and India are continuing their fight at the WTO. But with the world’s most powerful countries ranged against them, and without the support of Bill Gates—the single most influential unelected individual in public health—the chances of success are as slim.

This article was first published in The Continent, the pan-African weekly newspaper designed to be read and shared on WhatsApp.

Simon Allison

Simon Allison is the Africa editor for the Mail & Guardian in Johannesburg. He is also a research consultant for the Institute for Security Studies, and was previously senior Africa correspondent for the Daily Maverick. He specializes in African news and analysis, and has reported from across the continent. His work has appeared on the Guardian, Foreign Policy, NPR, Courrier International and Internazionale. He holds degrees from Rhodes University in South Africa and the School of Oriental and African Studies in London, and has lived and worked across Africa and the Middle East.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

Please select a donation method:



Share This Article